25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CDTX (Cidara) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cidara together

I guess you are interested in Cidara Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cidara’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cidara’s Price Targets

I'm going to help you getting a better view of Cidara Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cidara Therapeutics Inc

I send you an email if I find something interesting about Cidara Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cidara (30 sec.)










1.2. What can you expect buying and holding a share of Cidara? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$9.99
Expected worth in 1 year
$21.36
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$11.36
Return On Investment
23.2%

For what price can you sell your share?

Current Price per Share
$49.03
Expected price per share
$27.00 - $56.83
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cidara (5 min.)




Live pricePrice per Share (EOD)
$49.03
Intrinsic Value Per Share
$-58.50 - $-19.29
Total Value Per Share
$-48.51 - $-9.30

2.2. Growth of Cidara (5 min.)




Is Cidara growing?

Current yearPrevious yearGrowGrow %
How rich?$141.6m-$634.5k$138.5m100.5%

How much money is Cidara making?

Current yearPrevious yearGrowGrow %
Making money-$45.1m-$9.1m-$36m-79.8%
Net Profit Margin-7,401.5%-95.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Cidara (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#297 / 884

Most Revenue
#574 / 884

Most Profit
#777 / 884

Most Efficient
#819 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cidara?

Welcome investor! Cidara's management wants to use your money to grow the business. In return you get a share of Cidara.

First you should know what it really means to hold a share of Cidara. And how you can make/lose money.

Speculation

The Price per Share of Cidara is $49.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cidara.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cidara, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $9.99. Based on the TTM, the Book Value Change Per Share is $2.84 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cidara.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.66-3.4%-3.45-7.0%-0.70-1.4%-1.45-3.0%-1.34-2.7%-1.16-2.4%
Usd Book Value Change Per Share-2.60-5.3%2.845.8%-0.86-1.8%0.801.6%0.290.6%0.280.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.60-5.3%2.845.8%-0.86-1.8%0.801.6%0.290.6%0.280.6%
Usd Price Per Share21.54-17.78-0.95-6.50-4.78-6.08-
Price to Earnings Ratio-3.25--1.90--0.35--0.63--0.48--1.23-
Price-to-Total Gains Ratio-8.29--2.26--1.21--1.18--1.31--3.44-
Price to Book Ratio2.16-1.67-0.14-0.38-0.36-0.82-
Price-to-Total Gains Ratio-8.29--2.26--1.21--1.18--1.31--3.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share49.03
Number of shares20
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.840.29
Usd Total Gains Per Share2.840.29
Gains per Quarter (20 shares)56.825.85
Gains per Year (20 shares)227.2823.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1022721702313
2045544404736
3068267107059
4090989809482
50113611250117105
60136413520140128
70159115790164151
80181818060187174
90204620330211197
100227322600234220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%4.036.00.010.0%4.042.00.08.7%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.028.00.030.0%13.031.02.028.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.028.00.030.0%13.031.02.028.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cidara Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.5982.841-191%-0.860-67%0.801-424%0.292-988%0.284-1016%
Book Value Per Share--9.99310.399-4%-0.049+100%3.611+177%2.647+278%4.032+148%
Current Ratio--3.8693.978-3%1.305+197%2.330+66%2.083+86%6.537-41%
Debt To Asset Ratio--0.2610.258+1%1.027-75%0.745-65%0.755-65%0.486-46%
Debt To Equity Ratio--0.3530.349+1%2.577-86%1.677-79%3.501-90%1.907-81%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--423493584.220351844142.555+20%-19128435.810+105%109947967.617+285%76866215.893+451%118966903.922+256%
Eps---1.656-3.445+108%-0.703-58%-1.454-12%-1.336-19%-1.163-30%
Ev To Ebitda Ratio---4.198-3.969-5%0.031-13451%-1.310-69%-0.866-79%-2.092-50%
Free Cash Flow Per Share---1.548-3.664+137%-0.359-77%-1.443-7%-1.207-22%-1.012-35%
Free Cash Flow To Equity Per Share---1.5432.836-154%-0.198-87%0.944-263%0.426-462%0.244-733%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---19.289----------
Intrinsic Value_10Y_min---58.503----------
Intrinsic Value_1Y_max---3.747----------
Intrinsic Value_1Y_min---5.824----------
Intrinsic Value_3Y_max---9.876----------
Intrinsic Value_3Y_min---17.637----------
Intrinsic Value_5Y_max---14.338----------
Intrinsic Value_5Y_min---29.508----------
Market Cap635909294.000+52%305388584.220237075392.555+29%12276564.190+2388%86514217.617+253%63297765.893+382%79492853.922+284%
Net Profit Margin----74.0150%-0.9510%-25.2400%-16.8080%-8.7370%
Operating Margin----9.2060%-0.7130%-3.5500%-3.7840%-2.2260%
Operating Ratio---9.440-100%2.021-100%4.400-100%6.075-100%3.748-100%
Pb Ratio4.906+56%2.1551.670+29%0.136+1480%0.380+467%0.357+504%0.816+164%
Pe Ratio-7.401-128%-3.252-1.899-42%-0.355-89%-0.628-81%-0.477-85%-1.230-62%
Price Per Share49.030+56%21.54017.778+21%0.947+2176%6.503+231%4.780+351%6.079+254%
Price To Free Cash Flow Ratio-7.917-128%-3.478-1.940-44%-0.258-93%-0.779-78%-0.764-78%-1.604-54%
Price To Total Gains Ratio-18.871-128%-8.291-2.262-73%-1.205-85%-1.179-86%-1.309-84%-3.441-58%
Quick Ratio--3.4803.615-4%0.997+249%2.042+70%1.819+91%7.730-55%
Return On Assets---0.122-0.244+100%-0.148+20%-0.164+34%-0.198+62%-0.174+42%
Return On Equity---0.166-0.326+97%-0.455+174%-0.141-15%-0.917+453%-0.559+238%
Total Gains Per Share---2.5982.841-191%-0.860-67%0.801-424%0.292-988%0.284-1016%
Usd Book Value--141682000.000137889000.000+3%-634500.000+100%47838083.333+196%34936500.000+306%52599900.000+169%
Usd Book Value Change Per Share---2.5982.841-191%-0.860-67%0.801-424%0.292-988%0.284-1016%
Usd Book Value Per Share--9.99310.399-4%-0.049+100%3.611+177%2.647+278%4.032+148%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--423493584.220351844142.555+20%-19128435.810+105%109947967.617+285%76866215.893+451%118966903.922+256%
Usd Eps---1.656-3.445+108%-0.703-58%-1.454-12%-1.336-19%-1.163-30%
Usd Free Cash Flow---21950000.000-47986250.000+119%-4653000.000-79%-18870666.667-14%-15742300.000-28%-13172300.000-40%
Usd Free Cash Flow Per Share---1.548-3.664+137%-0.359-77%-1.443-7%-1.207-22%-1.012-35%
Usd Free Cash Flow To Equity Per Share---1.5432.836-154%-0.198-87%0.944-263%0.426-462%0.244-733%
Usd Market Cap635909294.000+52%305388584.220237075392.555+29%12276564.190+2388%86514217.617+253%63297765.893+382%79492853.922+284%
Usd Price Per Share49.030+56%21.54017.778+21%0.947+2176%6.503+231%4.780+351%6.079+254%
Usd Profit---23480000.000-45183000.000+92%-9116500.000-61%-19065833.333-19%-17451100.000-26%-14836550.000-37%
Usd Revenue---75500.000-100%11594500.000-100%10830500.000-100%9809200.000-100%5490725.000-100%
Usd Total Gains Per Share---2.5982.841-191%-0.860-67%0.801-424%0.292-988%0.284-1016%
 EOD+5 -3MRQTTM+17 -18YOY+17 -173Y+16 -195Y+17 -1810Y+15 -20

3.3 Fundamental Score

Let's check the fundamental score of Cidara Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.401
Price to Book Ratio (EOD)Between0-14.906
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.480
Current Ratio (MRQ)Greater than13.869
Debt to Asset Ratio (MRQ)Less than10.261
Debt to Equity Ratio (MRQ)Less than10.353
Return on Equity (MRQ)Greater than0.15-0.166
Return on Assets (MRQ)Greater than0.05-0.122
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cidara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.645
Ma 20Greater thanMa 5032.219
Ma 50Greater thanMa 10026.074
Ma 100Greater thanMa 20023.740
OpenGreater thanClose48.500
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Cidara Therapeutics Inc

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Fundamental data was last updated by Penke on 2025-06-19 02:11:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cidara earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cidara to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cidara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-7,401.5%+7,401.5%
TTM-7,401.5%YOY-95.1%-7,306.4%
TTM-7,401.5%5Y-1,680.8%-5,720.7%
5Y-1,680.8%10Y-873.7%-807.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM-7,401.5%-141.4%-7,260.1%
YOY-95.1%-186.1%+91.0%
3Y-2,524.0%-248.3%-2,275.7%
5Y-1,680.8%-338.6%-1,342.2%
10Y-873.7%-488.9%-384.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cidara is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cidara to theΒ Biotechnology industry mean.
  • -12.2% Return on Assets means thatΒ Cidara generatedΒ $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cidara Therapeutics Inc:

  • The MRQ is -12.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.2%TTM-24.4%+12.2%
TTM-24.4%YOY-14.8%-9.7%
TTM-24.4%5Y-19.8%-4.7%
5Y-19.8%10Y-17.4%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.2%-11.5%-0.7%
TTM-24.4%-11.6%-12.8%
YOY-14.8%-11.4%-3.4%
3Y-16.4%-11.8%-4.6%
5Y-19.8%-12.1%-7.7%
10Y-17.4%-13.8%-3.6%
4.3.1.3. Return on Equity

Shows how efficient Cidara is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cidara to theΒ Biotechnology industry mean.
  • -16.6% Return on Equity means Cidara generated $-0.17Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cidara Therapeutics Inc:

  • The MRQ is -16.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -32.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.6%TTM-32.6%+16.0%
TTM-32.6%YOY-45.5%+12.9%
TTM-32.6%5Y-91.7%+59.1%
5Y-91.7%10Y-55.9%-35.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.6%-13.6%-3.0%
TTM-32.6%-14.9%-17.7%
YOY-45.5%-14.4%-31.1%
3Y-14.1%-17.0%+2.9%
5Y-91.7%-17.9%-73.8%
10Y-55.9%-20.1%-35.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cidara Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cidara is operatingΒ .

  • Measures how much profit Cidara makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cidara to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cidara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-920.6%+920.6%
TTM-920.6%YOY-71.3%-849.4%
TTM-920.6%5Y-378.4%-542.2%
5Y-378.4%10Y-222.6%-155.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-920.6%-250.3%-670.3%
YOY-71.3%-205.1%+133.8%
3Y-355.0%-220.2%-134.8%
5Y-378.4%-342.6%-35.8%
10Y-222.6%-475.5%+252.9%
4.3.2.2. Operating Ratio

Measures how efficient Cidara is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.440-9.440
TTM9.440YOY2.021+7.419
TTM9.4405Y6.075+3.364
5Y6.07510Y3.748+2.327
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM9.4402.704+6.736
YOY2.0213.063-1.042
3Y4.4003.576+0.824
5Y6.0754.713+1.362
10Y3.7486.512-2.764
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cidara Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cidara is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.87Β means the company has $3.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 3.869. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.978. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.869TTM3.978-0.108
TTM3.978YOY1.305+2.673
TTM3.9785Y2.083+1.894
5Y2.08310Y6.537-4.453
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8693.661+0.208
TTM3.9783.786+0.192
YOY1.3054.121-2.816
3Y2.3304.680-2.350
5Y2.0835.765-3.682
10Y6.5376.150+0.387
4.4.3.2. Quick Ratio

Measures if Cidara is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cidara to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.48Β means the company can pay off $3.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 3.480. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.615. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.480TTM3.615-0.136
TTM3.615YOY0.997+2.618
TTM3.6155Y1.819+1.796
5Y1.81910Y7.730-5.910
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4802.826+0.654
TTM3.6153.128+0.487
YOY0.9973.782-2.785
3Y2.0424.304-2.262
5Y1.8195.703-3.884
10Y7.7306.454+1.276
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cidara Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CidaraΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cidara to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26Β means that Cidara assets areΒ financed with 26.1% credit (debt) and the remaining percentage (100% - 26.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.261. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.258. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.261TTM0.258+0.003
TTM0.258YOY1.027-0.768
TTM0.2585Y0.755-0.497
5Y0.75510Y0.486+0.269
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2610.324-0.063
TTM0.2580.347-0.089
YOY1.0270.327+0.700
3Y0.7450.339+0.406
5Y0.7550.349+0.406
10Y0.4860.382+0.104
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cidara is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cidara to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 35.3% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cidara Therapeutics Inc:

  • The MRQ is 0.353. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.349. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.353TTM0.349+0.004
TTM0.349YOY2.577-2.228
TTM0.3495Y3.501-3.152
5Y3.50110Y1.907+1.594
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3530.383-0.030
TTM0.3490.436-0.087
YOY2.5770.410+2.167
3Y1.6770.446+1.231
5Y3.5010.460+3.041
10Y1.9070.509+1.398
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Cidara generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cidara to theΒ Biotechnology industry mean.
  • A PE ratio of -3.25 means the investor is paying $-3.25Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cidara Therapeutics Inc:

  • The EOD is -7.401. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.252. Based on the earnings, the company is expensive. -2
  • The TTM is -1.899. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.401MRQ-3.252-4.150
MRQ-3.252TTM-1.899-1.353
TTM-1.899YOY-0.355-1.544
TTM-1.8995Y-0.477-1.422
5Y-0.47710Y-1.230+0.753
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.401-2.197-5.204
MRQ-3.252-2.027-1.225
TTM-1.899-2.527+0.628
YOY-0.355-3.733+3.378
3Y-0.628-3.717+3.089
5Y-0.477-6.036+5.559
10Y-1.230-6.649+5.419
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cidara Therapeutics Inc:

  • The EOD is -7.917. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.478. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.940. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.917MRQ-3.478-4.439
MRQ-3.478TTM-1.940-1.538
TTM-1.940YOY-0.258-1.682
TTM-1.9405Y-0.764-1.176
5Y-0.76410Y-1.604+0.840
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.917-3.007-4.910
MRQ-3.478-2.704-0.774
TTM-1.940-3.627+1.687
YOY-0.258-4.334+4.076
3Y-0.779-5.070+4.291
5Y-0.764-8.532+7.768
10Y-1.604-9.305+7.701
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cidara is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.16 means the investor is paying $2.16Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cidara Therapeutics Inc:

  • The EOD is 4.906. Based on the equity, the company is fair priced.
  • The MRQ is 2.155. Based on the equity, the company is underpriced. +1
  • The TTM is 1.670. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.906MRQ2.155+2.751
MRQ2.155TTM1.670+0.486
TTM1.670YOY0.136+1.533
TTM1.6705Y0.357+1.313
5Y0.35710Y0.816-0.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.9061.921+2.985
MRQ2.1551.843+0.312
TTM1.6702.113-0.443
YOY0.1362.467-2.331
3Y0.3802.541-2.161
5Y0.3573.666-3.309
10Y0.8164.311-3.495
4.6.2. Total Gains per Share

2.4. Latest News of Cidara Therapeutics Inc

Does Cidara Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Cidara Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-01
22:59
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Read
2025-06-26
23:28
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesRead
2025-06-26
23:15
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesRead
2025-06-25
02:12
Cidara Announces Pricing of Upsized Public Offering of Common StockRead
2025-06-25
02:00
Cidara Announces Pricing of Upsized Public Offering of Common StockRead
2025-06-23
22:15
Cidara Announces Proposed Public Offering of Common StockRead
2025-06-23
21:43
Cidara more than doubles on phase 2 flu preventative dataRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cidara Therapeutics Inc.

4.8.1. Institutions holding Cidara Therapeutics Inc

Institutions are holding 86.201% of the shares of Cidara Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31RA Capital Management, LLC8.42570.3931109279600
2025-03-31VR Adviser, LLC8.10741.9272105151828579537.3235
2025-03-31TCG Crossover Management, LLC7.75572.9556100590100
2025-03-31Adage Capital Partners Gp LLC7.63310.0395990000620046167.6008
2025-03-31Bvf Inc7.12920.8118924642-168154-15.3875
2025-03-31Bain Capital Life Sciences Investors, LLC5.42092.240670308000
2025-03-31Vivo Capital, LLC5.27591.9521684276136762.0394
2025-03-31Vanguard Group Inc3.92890.0002509576292072134.2835
2025-03-31Vestal Point Capital LP3.89010.77615045425045420
2025-03-31Susquehanna International Group, LLP2.64060.0013342476299853703.5005
2025-03-31Citadel Advisors Llc2.21880.00122877752877750
2025-03-31Ikarian Capital, LLC1.91940.6608248940195000361.5128
2025-03-31Longwood Capital Partners LLC0.96923.140212570871235130.7712
2025-03-31Aberdeen Group PLC0.9320.00511208791208790
2025-03-31Point72 Asset Management, L.P.0.87780.00561138551077071751.9031
2025-03-31Checkpoint Capital LP0.80481.2336104380-92569-47.0015
2025-03-31Renaissance Technologies Corp0.71330.00392517-3100-3.2421
2025-03-31BOOTHBAY FUND MANAGEMENT, LLC0.60970.04497908163480406.897
2025-03-31Millennium Management LLC0.49020.0007635802762076.8076
2025-03-315AM Venture Management, LLC0.43740.46215672500
Total 70.180116.65479102247+2625857+28.8%

4.9.2. Funds holding Cidara Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv3.21610.000541711700
2025-05-31abrdn Healthcare Investors0.64860.28411700
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.63580.00178246600
2025-05-31abrdn Life Sciences Investors0.28340.19913676200
2025-02-28Vifag 2002 SICAV0.20560.96482666100
2025-04-30Fidelity Extended Market Index0.20340.001526379-252-0.9463
2025-05-31Avantis US Small Cap Equity ETF0.11760.021915247550.362
2025-03-31Extended Equity Market Fund K0.08330.001810800330.3065
2025-04-30Fidelity Total Market Index0.07130.0002925000
2025-05-31iShares Micro-Cap ETF0.06760.0245877000
2025-05-31A4Investments SICAV SIF ACCI IlanaA2EURH0.06174.2844800000
2025-03-31Northern Small Cap Core I0.05630.04447299-301-3.9605
2025-04-30Fidelity Series Total Market Index0.05240.000267942053.1112
2025-03-31Northern Trust Extended Eq Market Idx0.04260.0015552400
2025-03-31NT Ext Equity Mkt Idx Fd - L0.04260.0015552400
2025-04-30Spartan Extended Market Index Pool F0.04210.001654552524.8434
2025-05-30Invesco RAFI US 1500 Small-Mid ETF0.03890.00485045-2-0.0396
2025-04-30Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03720.0004482900
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.03390.0016439700
2025-04-30Fidelity Nasdaq Composite Index0.03060.0005396700
Total 5.9715.7569774403-100.0%

5.3. Insider Transactions

Insiders are holding 1.738% of the shares of Cidara Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-11Leslie TariSELL177321.96
2025-03-11Shane WardSELL166421.96
2024-09-11Taylor SandisonSELL92411.64
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets191,727
Total Liabilities50,045
Total Stockholder Equity141,682
 As reported
Total Liabilities 50,045
Total Stockholder Equity+ 141,682
Total Assets = 191,727

Assets

Total Assets191,727
Total Current Assets188,848
Long-term Assets2,879
Total Current Assets
Cash And Cash Equivalents 168,150
Net Receivables 1,694
Other Current Assets 19,004
Total Current Assets  (as reported)188,848
Total Current Assets  (calculated)188,848
+/-0
Long-term Assets
Property Plant Equipment 2,783
Long-term Assets Other 96
Long-term Assets  (as reported)2,879
Long-term Assets  (calculated)2,879
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities48,809
Long-term Liabilities1,236
Total Stockholder Equity141,682
Total Current Liabilities
Short-term Debt 1,437
Accounts payable 4,897
Other Current Liabilities 21,748
Total Current Liabilities  (as reported)48,809
Total Current Liabilities  (calculated)28,082
+/- 20,727
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,236
Long-term Liabilities  (as reported)1,236
Long-term Liabilities  (calculated)1,236
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -634,738
Other Stockholders Equity 776,419
Total Stockholder Equity (as reported)141,682
Total Stockholder Equity (calculated)141,682
+/-0
Other
Capital Stock1
Cash and Short Term Investments 168,150
Common Stock Shares Outstanding 14,178
Liabilities and Stockholders Equity 191,727
Net Debt -165,477
Net Invested Capital 141,682
Net Working Capital 140,039
Property Plant and Equipment Gross 2,783
Short Long Term Debt Total 2,673



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
201
0
0
26,631
24,350
60,783
123,953
116,988
109,974
99,223
90,024
82,232
106,962
92,763
81,158
67,436
79,035
70,247
107,008
92,809
79,112
64,313
51,752
81,696
68,976
84,097
73,403
63,669
60,424
54,210
63,744
51,206
75,325
55,295
39,524
66,858
47,593
81,736
67,986
63,468
67,030
52,716
173,357
162,331
214,796
191,727
191,727214,796162,331173,35752,71667,03063,46867,98681,73647,59366,85839,52455,29575,32551,20663,74454,21060,42463,66973,40384,09768,97681,69651,75264,31379,11292,809107,00870,24779,03567,43681,15892,763106,96282,23290,02499,223109,974116,988123,95360,78324,35026,63100201
   > Total Current Assets 
198
185
0
25,773
23,013
58,402
123,050
115,365
108,218
97,517
88,231
80,579
105,398
91,281
79,803
66,203
77,670
68,990
105,994
91,961
77,129
60,276
47,746
77,488
65,814
80,621
70,039
60,187
57,191
51,301
61,076
47,276
71,698
52,007
36,546
63,899
45,094
79,488
62,240
57,704
60,855
46,834
168,588
156,771
210,737
188,848
188,848210,737156,771168,58846,83460,85557,70462,24079,48845,09463,89936,54652,00771,69847,27661,07651,30157,19160,18770,03980,62165,81477,48847,74660,27677,12991,961105,99468,99077,67066,20379,80391,281105,39880,57988,23197,517108,218115,365123,05058,40223,01325,7730185198
       Cash And Cash Equivalents 
185
-185
0
25,568
22,796
58,124
122,301
64,471
107,514
51,704
29,271
24,622
104,619
82,198
78,012
54,276
75,314
52,218
88,954
83,780
74,562
57,407
44,573
73,824
60,268
64,314
54,826
45,520
35,912
42,863
48,284
36,601
62,273
36,488
24,637
53,078
32,731
47,976
50,430
48,670
35,778
29,018
164,369
127,386
189,825
168,150
168,150189,825127,386164,36929,01835,77848,67050,43047,97632,73153,07824,63736,48862,27336,60148,28442,86335,91245,52054,82664,31460,26873,82444,57357,40774,56283,78088,95452,21875,31454,27678,01282,198104,61924,62229,27151,704107,51464,471122,30158,12422,79625,5680-185185
       Short-term Investments 
0
370
0
0
44,952
0
0
49,947
44,952
44,954
57,818
54,687
19,252
7,888
0
9,876
14,501
13,973
14,246
4,494
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000004,49414,24613,97314,5019,87607,88819,25254,68757,81844,95444,95249,9470044,952003700
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
190
190
190
215
321
321
288
41
62
1,271
1,271
1,446
1,902
10
6,307
5,954
6,519
11,175
11
3,157
3,872
5,356
8,783
4,833
5,042
5,833
25,826
5,483
2,855
14,075
7,281
2,349
1,699
1,694
1,694
1,6941,6941,6992,3497,28114,0752,8555,48325,8265,8335,0424,8338,7835,3563,8723,1571111,1756,5195,9546,307101,9021,4461,2711,271624128832132121519019019000000000000
       Other Current Assets 
13
0
0
205
217
278
749
947
704
859
1,142
2,540
779
1,195
3,152
3,460
2,035
2,511
2,753
7,374
2,567
5,738
6,346
7,328
15,536
10,000
9,259
8,148
10,104
8,427
9,635
6,803
6,662
6,736
7,076
11,558
13,060
5,686
4,373
3,712
1,712
3,266
1,870
27,686
19,218
19,004
19,00419,21827,6861,8703,2661,7123,7124,3735,68613,06011,5587,0766,7366,6626,8039,6358,42710,1048,1489,25910,00015,5367,3286,3465,7382,5677,3742,7532,5112,0353,4603,1521,1957792,5401,1428597049477492782172050013
   > Long-term Assets 
3
-185
0
858
1,337
2,381
903
1,623
1,756
1,706
1,793
1,653
1,564
1,482
1,355
1,233
1,365
1,257
1,014
848
1,983
4,037
4,006
4,208
3,162
3,476
3,364
3,482
3,233
2,909
2,668
3,930
3,627
3,288
2,978
2,959
2,499
2,248
5,746
5,764
6,175
5,882
4,769
5,560
4,059
2,879
2,8794,0595,5604,7695,8826,1755,7645,7462,2482,4992,9592,9783,2883,6273,9302,6682,9093,2333,4823,3643,4763,1624,2084,0064,0371,9838481,0141,2571,3651,2331,3551,4821,5641,6531,7931,7061,7561,6239032,3811,3378580-1853
       Property Plant Equipment 
0
0
0
756
863
814
831
1,550
1,684
1,634
1,603
1,463
1,374
1,292
1,165
1,043
1,044
936
824
786
712
2,766
2,560
2,306
2,061
1,841
1,729
1,459
1,210
948
707
2,756
2,543
2,269
1,965
1,664
1,427
1,187
4,685
4,711
5,127
4,895
4,665
4,318
3,963
2,783
2,7833,9634,3184,6654,8955,1274,7114,6851,1871,4271,6641,9652,2692,5432,7567079481,2101,4591,7291,8412,0612,3062,5602,7667127868249361,0441,0431,1651,2921,3741,4631,6031,6341,6841,550831814863756000
       Other Assets 
3
0
0
0
474
1,567
72
73
72
72
190
190
190
190
190
190
321
321
190
62
1,271
1,271
1,446
1,902
1,101
1,635
1,635
3,086
2,891
1,961
1,961
1,174
1,084
1,019
1,013
1,295
0
0
1,061
0
0
0
0
0
-782
0
0-782000001,061001,2951,0131,0191,0841,1741,9611,9612,8913,0861,6351,6351,1011,9021,4461,2711,27162190321321190190190190190190727273721,5674740003
> Total Liabilities 
1,599
0
0
1,020
3,247
78,309
3,096
4,363
6,062
4,145
5,215
8,317
18,783
16,774
19,894
16,863
19,291
19,328
24,870
22,877
19,973
20,451
19,970
32,734
31,141
30,345
32,051
34,116
49,709
52,318
47,955
52,364
53,752
50,338
47,485
57,791
50,497
54,899
52,572
55,430
75,240
70,496
42,421
46,701
51,488
50,045
50,04551,48846,70142,42170,49675,24055,43052,57254,89950,49757,79147,48550,33853,75252,36447,95552,31849,70934,11632,05130,34531,14132,73419,97020,45119,97322,87724,87019,32819,29116,86319,89416,77418,7838,3175,2154,1456,0624,3633,09678,3093,2471,020001,599
   > Total Current Liabilities 
116
0
0
1,020
3,213
3,809
3,068
4,275
5,974
4,056
5,125
8,232
8,909
6,886
10,658
8,617
12,085
11,519
14,918
13,562
19,892
18,897
18,608
31,579
30,199
29,629
31,567
33,871
38,564
39,966
33,887
33,490
34,017
32,105
31,455
33,049
29,972
35,663
31,420
35,620
67,418
65,425
39,643
44,339
49,554
48,809
48,80949,55444,33939,64365,42567,41835,62031,42035,66329,97233,04931,45532,10534,01733,49033,88739,96638,56433,87131,56729,62930,19931,57918,60818,89719,89213,56214,91811,51912,0858,61710,6586,8868,9098,2325,1254,0565,9744,2753,0683,8093,2131,02000116
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
667
1,667
2,667
2,083
5,374
667
9,928
11,398
11,472
11,538
11,601
11,662
10,990
9,949
8,901
7,348
5,776
5,758
4,887
3,861
2,836
2,554
2,528
1,001
942
2,102
0
1,464
3,044
1,581
1,642
1,437
1,4371,6421,5813,0441,46402,1029421,0012,5282,5542,8363,8614,8875,7585,7767,3488,9019,94910,99011,66211,60111,53811,47211,3989,9286675,3742,0832,6671,6676679,8139,794000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
9,832
1,667
2,667
2,083
9,910
667
9,928
9,938
9,948
9,958
9,965
9,966
9,234
8,129
7,023
5,916
4,808
3,700
2,591
1,481
370
0
0
0
0
0
0
0
0
0
0
0
000000000003701,4812,5913,7004,8085,9167,0238,1299,2349,9669,9659,9589,9489,9389,9286679,9102,0832,6671,6679,8329,8139,794000000000000
       Accounts payable 
32
0
0
431
1,177
1,696
854
1,338
3,095
1,266
1,517
2,957
2,909
1,912
4,817
1,777
2,590
2,999
2,611
2,439
2,846
1,713
1,787
2,679
1,887
2,560
2,933
2,024
4,568
3,215
2,587
3,242
1,301
2,861
3,091
4,244
1,447
3,980
1,899
3,661
3,772
5,055
2,288
2,967
3,608
4,897
4,8973,6082,9672,2885,0553,7723,6611,8993,9801,4474,2443,0912,8611,3013,2422,5873,2154,5682,0242,9332,5601,8872,6791,7871,7132,8462,4392,6112,9992,5901,7774,8171,9122,9092,9571,5171,2663,0951,3388541,6961,1774310032
       Other Current Liabilities 
84
0
0
589
2,036
2,113
2,214
2,937
2,879
2,790
3,608
5,275
6,000
4,974
5,174
5,173
6,828
6,437
12,307
10,456
7,118
5,786
5,349
6,462
6,908
5,128
6,448
8,807
11,230
13,992
11,063
11,460
13,909
11,123
10,798
11,002
-151
14,921
13,604
15,178
24,665
13,964
8,228
13,502
18,259
21,748
21,74818,25913,5028,22813,96424,66515,17813,60414,921-15111,00210,79811,12313,90911,46011,06313,99211,2308,8076,4485,1286,9086,4625,3495,7867,11810,45612,3076,4376,8285,1735,1744,9746,0005,2753,6082,7902,8792,9372,2142,1132,0365890084
   > Long-term Liabilities 
1,483
0
0
0
34
74,500
28
88
6,062
89
90
85
9,874
9,888
9,236
8,246
7,206
7,809
9,952
9,315
81
1,554
1,362
1,155
942
716
484
245
11,145
12,352
14,068
18,874
19,735
18,233
16,030
24,742
20,525
19,236
21,152
19,810
7,822
5,071
2,778
2,362
1,934
1,236
1,2361,9342,3622,7785,0717,82219,81021,15219,23620,52524,74216,03018,23319,73518,87414,06812,35211,1452454847169421,1551,3621,554819,3159,9527,8097,2068,2469,2369,8889,8748590896,062882874,500340001,483
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
9,794
9,813
9,165
8,185
7,206
7,809
9,910
9,253
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000009,2539,9107,8097,2068,1859,1659,8139,794000000000000
       Long term Debt 
1,483
0
0
0
9,794
0
0
0
0
0
0
0
9,794
9,813
9,165
8,185
7,206
7,809
9,910
9,253
0
1,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,55409,2539,9107,8097,2068,1859,1659,8139,79400000009,7940001,483
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
-9,794
-9,813
-667
-1,667
-2,667
-2,083
-5,374
-667
-9,928
-9,114
-9,348
-9,593
-9,841
-10,098
-9,628
-8,794
-7,962
-6,632
-5,292
-3,109
-2,417
-1,667
-924
-933
-1,211
0
3,601
2,255
4,877
3,183
1,256
2,362
1,934
1,236
1,2361,9342,3621,2563,1834,8772,2553,6010-1,211-933-924-1,667-2,417-3,109-5,292-6,632-7,962-8,794-9,628-10,098-9,841-9,593-9,348-9,114-9,928-667-5,374-2,083-2,667-1,667-667-9,813-9,794000000000000
       Warrants
0
0
0
0
0
74,469
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000074,46900000
       Other Liabilities 
0
0
0
0
34
31
28
88
88
89
90
85
80
75
71
61
0
0
42
62
81
0
0
0
31,141
0
0
0
11,145
12,352
14,068
17,254
18,413
17,229
15,351
24,398
0
0
17,551
0
0
0
0
0
0
0
000000017,5510024,39815,35117,22918,41317,25414,06812,35211,14500031,141000816242006171758085908988882831340000
       Long-term Liabilities Other 
0
0
0
0
0
31
28
88
88
89
90
0
80
0
0
0
0
0
42
62
81
1,554
1,362
1,155
942
716
484
245
11,145
12,352
14,068
0
0
0
0
0
20,525
19,236
3,601
0
0
0
0
0
0
0
00000003,60119,23620,5250000014,06812,35211,1452454847169421,1551,3621,5548162420000080090898888283100000
> Total Stockholder Equity
-1,398
-1,398
0
25,573
21,103
-17,526
120,857
112,625
103,912
95,078
84,809
73,915
88,179
75,989
61,264
50,573
59,744
50,919
82,138
69,932
59,139
43,862
31,782
48,962
37,835
53,752
41,352
29,553
10,715
1,892
15,789
-1,158
21,573
4,957
-7,961
9,067
-2,904
26,837
15,414
8,038
-8,210
-17,780
130,936
115,630
163,308
141,682
141,682163,308115,630130,936-17,780-8,2108,03815,41426,837-2,9049,067-7,9614,95721,573-1,15815,7891,89210,71529,55341,35253,75237,83548,96231,78243,86259,13969,93282,13850,91959,74450,57361,26475,98988,17973,91584,80995,078103,912112,625120,857-17,52621,10325,5730-1,398-1,398
   Common Stock
0
0
0
3
1
3
4
4
1
1
1
1
2
2
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
5
5
5
7
7
7
7
7
9
9
9
0
1
1
1
1
1
1111109997777755544443333333222222111144313000
   Retained Earnings -634,738-611,258-558,951-542,966-451,757-441,431-424,286-416,114-403,757-406,966-393,589-408,567-395,448-377,167-360,364-342,281-352,992-334,700-313,066-295,434-277,128-259,827-245,804-248,843-235,296-218,735-206,393-192,774-166,138-149,390-135,962-123,705-107,060-93,662-79,268-67,041-55,286-45,497-35,629-26,455-20,041-13,304-8,65500-1,410
   Capital Surplus 
0
0
0
0
0
2,512
147,308
148,255
149,416
150,365
151,853
153,199
181,840
183,051
184,967
186,534
209,140
217,073
274,912
276,323
277,871
279,155
280,622
294,763
297,659
330,876
336,782
342,615
345,411
354,879
358,065
0
0
0
0
0
404,055
430,585
431,519
0
0
0
0
0
0
0
0000000431,519430,585404,05500000358,065354,879345,411342,615336,782330,876297,659294,763280,622279,155277,871276,323274,912217,073209,140186,534184,967183,051181,840153,199151,853150,365149,416148,255147,3082,51200000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
12
0
0
1,677
1,859
2,512
147,308
148,255
149,416
150,365
151,853
153,199
181,840
183,051
184,967
186,534
209,140
217,073
274,912
276,323
277,871
279,155
280,622
294,763
297,659
330,876
336,782
342,615
345,411
354,879
358,065
359,201
398,733
400,398
400,599
402,649
404,055
430,585
431,519
432,315
0
433,976
673,901
674,580
774,565
776,419
776,419774,565674,580673,901433,9760432,315431,519430,585404,055402,649400,599400,398398,733359,201358,065354,879345,411342,615336,782330,876297,659294,763280,622279,155277,871276,323274,912217,073209,140186,534184,967183,051181,840153,199151,853150,365149,416148,255147,3082,5121,8591,6770012



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,275
Cost of Revenue-84,883
Gross Profit1,042-83,608
 
Operating Income (+$)
Gross Profit1,042
Operating Expense-92,494
Operating Income-176,102-91,452
 
Operating Expense (+$)
Research Development71,879
Selling General Administrative20,615
Selling And Marketing Expenses0
Operating Expense92,49492,494
 
Net Interest Income (+$)
Interest Income5,811
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,811
 
Pretax Income (+$)
Operating Income-176,102
Net Interest Income5,811
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-170,291-181,913
EBIT - interestExpense = -176,335
-169,827
-169,827
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-176,335-170,291
Earnings Before Interest and Taxes (EBITDA)-176,102
 
After tax Income (+$)
Income Before Tax-170,291
Tax Provision-0
Net Income From Continuing Ops-170,291-170,291
Net Income-169,827
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses177,377
Total Other Income/Expenses Net5,811-5,811
 

Technical Analysis of Cidara
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cidara. The general trend of Cidara is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cidara's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cidara Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cidara Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 56.83.

The bearish price targets are: 28.42 > 27.64 > 27.00.

Know someone who trades $CDTX? Share this with them.πŸ‘‡

Cidara Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cidara Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cidara Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cidara Therapeutics Inc. The current macd is 6.99042244.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cidara price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cidara. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cidara price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cidara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCidara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cidara Therapeutics Inc. The current adx is 40.26.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cidara shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Cidara Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cidara Therapeutics Inc. The current sar is 26.93.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cidara Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cidara Therapeutics Inc. The current rsi is 80.64. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Cidara Therapeutics Inc Daily Relative Strength Index (RSI) ChartCidara Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cidara Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cidara price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Cidara Therapeutics Inc Daily Stochastic Oscillator ChartCidara Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cidara Therapeutics Inc. The current cci is 97.06.

Cidara Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCidara Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cidara Therapeutics Inc. The current cmo is 65.70.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cidara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCidara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cidara Therapeutics Inc. The current willr is -21.26821712.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cidara is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cidara Therapeutics Inc Daily Williams %R ChartCidara Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cidara Therapeutics Inc.

Cidara Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cidara Therapeutics Inc. The current atr is 4.22400293.

Cidara Therapeutics Inc Daily Average True Range (ATR) ChartCidara Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cidara Therapeutics Inc. The current obv is 28,294,745.

Cidara Therapeutics Inc Daily On-Balance Volume (OBV) ChartCidara Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cidara Therapeutics Inc. The current mfi is 59.31.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cidara Therapeutics Inc Daily Money Flow Index (MFI) ChartCidara Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cidara Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-05-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cidara Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cidara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.645
Ma 20Greater thanMa 5032.219
Ma 50Greater thanMa 10026.074
Ma 100Greater thanMa 20023.740
OpenGreater thanClose48.500
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cidara with someone you think should read this too:
  • Are you bullish or bearish on Cidara? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cidara? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cidara Therapeutics Inc

I send you an email if I find something interesting about Cidara Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cidara Therapeutics Inc.

Receive notifications about Cidara Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.